Request for Comments on Research Across Borders: Proceedings of the International Research Panel of the Presidential Commission for the Study of Bioethical Issues, 55914-55915 [2011-23030]
Download as PDF
55914
Federal Register / Vol. 76, No. 175 / Friday, September 9, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
HIT Policy Committee’s Workgroup
Meetings; Notice of Meetings
Office of the National
Coordinator for Health Information
Technology, HHS.
ACTION: Notice of meetings.
AGENCY:
mstockstill on DSK4VPTVN1PROD with NOTICES
This notice announces forthcoming
subcommittee meetings of a federal
advisory committee of the Office of the
National Coordinator for Health
Information Technology (ONC). The
meetings will be open to the public via
dial-in access only.
Name of Committees: HIT Policy
Committee’s Workgroups: Meaningful Use,
Privacy & Security Tiger Team, Quality
Measures, Adoption/Certification, and
Information Exchange workgroups.
General Function of the Committee: To
provide recommendations to the National
Coordinator on a policy framework for the
development and adoption of a nationwide
health information technology infrastructure
that permits the electronic exchange and use
of health information as is consistent with
the Federal Health IT Strategic Plan and that
includes recommendations on the areas in
which standards, implementation
specifications, and certification criteria are
needed.
Date and Time: The HIT Policy Committee
Workgroups will hold the following public
meetings during October 2011: October 5 and
6, Meaningful Use Workgroup’s hearing and
public meeting, 9 a.m. to 4 p.m./ET; October
7th, Privacy & Security Tiger Team, 2 to 4
p.m./ET; October 18th Meaningful Use
Workgroup, 10 a.m. to 12 p.m./ET; October
20th, Privacy & Security Tiger Team, 2 to 4
p.m./ET.
Location: All workgroup meetings will be
available via webcast; for instructions on
how to listen via telephone or Web visit
https://healthit.hhs.gov. Please check the ONC
Web site for additional information or
revised schedules as it becomes available.
Detailed information on the October 5 and 6
Meaningful Use meetings can be found on
the ONC Web site as it becomes available.
Contact Person: Judy Sparrow, Office of the
National Coordinator, HHS, 330 C Street,
SW., Washington, DC 20201, 202–205–4528,
Fax: 202–690–6079, e-mail:
judy.sparrow@hhs.gov. Please call the contact
person for up-to-date information on these
meetings. A notice in the Federal Register
about last minute modifications that affect a
previously announced advisory committee
meeting cannot always be published quickly
enough to provide timely notice.
Agenda: The workgroups will be
discussing issues related to their specific
subject matter, e.g., meaningful use,
information exchange, privacy and security,
quality measures, governance, or adoption/
certification. If background materials are
associated with the workgroup meetings,
they will be posted on ONC’s Web site prior
to the meeting at https://healthit.hhs.gov.
VerDate Mar<15>2010
16:58 Sep 08, 2011
Jkt 223001
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
workgroups. Written submissions may be
made to the contact person on or before two
days prior to the workgroup’s meeting date.
Oral comments from the public will be
scheduled at the conclusion of each
workgroup meeting. Time allotted for each
presentation will be limited to three minutes.
If the number of speakers requesting to
comment is greater than can be reasonably
accommodated during the scheduled open
public session, ONC will take written
comments after the meeting until close of
business on that day.
If you require special accommodations due
to a disability, please contact Judy Sparrow
at least seven (7) days in advance of the
meeting.
ONC is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://healthit.hhs.gov
for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (Pub. L. 92–
463, 5 U.S.C., App. 2).
Dated: September 1, 2011.
Judith Sparrow,
Office of Programs and Coordination, Office
of the National Coordinator for Health
Information Technology.
[FR Doc. 2011–23049 Filed 9–8–11; 8:45 am]
BILLING CODE 4150–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Comments on Research
Across Borders: Proceedings of the
International Research Panel of the
Presidential Commission for the Study
of Bioethical Issues
Department of Health and
Human Services, Office of the Assistant
Secretary for Health, Presidential
Commission for the Study of Bioethical
Issues.
ACTION: Notice.
AGENCY:
The Presidential Commission
for the Study of Bioethical Issues is
requesting public comment on the
report of the International Research
Panel titled, Research Across Borders:
Proceedings of the International
Research Panel of the Presidential
Commission for the Study of Bioethical
Issues, available for review at https://
www.bioethics.gov.
SUMMARY:
To assure consideration,
comments must be received by October
11, 2011.
ADDRESSES: Individuals, groups, and
organizations interested in commenting
on this study may submit comments by
e-mail to info@bioethics.gov or by mail
to the following address: Public
DATES:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Commentary, Presidential Commission
for the Study of Bioethical Issues, 1425
New York Ave., NW., Suite C–100,
Washington, DC 20005.
FOR FURTHER INFORMATION CONTACT:
Hillary Wicai Viers, Communications
Director, Presidential Commission for
the Study of Bioethical Issues, 1425
New York Avenue, NW., Suite C–100,
Washington, DC 20005. Telephone:
202–233–3960. E-mail:
Hillary.Viers@bioethics.gov. Additional
information may be obtained at https://
www.bioethics.gov.
SUPPLEMENTARY INFORMATION: On
November 24, 2009, the President
established the Presidential Commission
for the Study of Bioethical Issues
(Commission) to advise him on
bioethical issues generated by novel and
emerging research in biomedicine and
related areas of science and technology.
The Commission is charged to identify
and promote policies and practices that
assure ethically responsible conduct of
scientific research, healthcare delivery,
and technological innovation. In
undertaking these duties, the
Commission seeks to identify and
examine specific bioethical, legal, and
social issues related to potential
scientific and technological advances;
examine diverse perspectives and
possibilities for international
collaboration on these issues; and
recommend legal, regulatory, or policy
actions as appropriate.
On October 1, 2010, the U.S.
Government disclosed that it had
supported research on sexually
transmitted diseases in Guatemala from
1946 to 1948 involving the intentional
infection of vulnerable human
populations. In response, President
Barack Obama directed the Presidential
Commission for the Study of Bioethical
Issues (the Commission) to ‘‘oversee a
thorough fact-finding investigation into
the specifics’’ of the U.S. Public Health
Service supported research, and to
conduct a review of current human
subjects protection ‘‘to determine if
Federal regulations and international
standards adequately guard the health
and well-being of participants in
scientific studies supported by the
Federal Government.’’ The President
asked specifically for assurance ‘‘that
current rules for research participants
protect people from harm or unethical
treatment, domestically as well as
internationally.’’ President Obama
directed the Commission to consult
with its counterparts in the global
community and to seek the insight of
international experts as part of its work
on contemporary protections for human
subjects of research. The Commission
E:\FR\FM\09SEN1.SGM
09SEN1
55915
Federal Register / Vol. 76, No. 175 / Friday, September 9, 2011 / Notices
assembled a subcommittee called the
International Research Panel, which met
three times in 2011. The proceedings of
the International Research Panel are
now available for public review and
comment at the Commission’s Web site,
www.bioethics.gov.
Please address comments by e-mail to
info@bioethics.gov, or by mail to the
following address: Public Commentary,
Presidential Commission for the Study
of Bioethical Issues, 1425 New York
Ave., NW., Suite C–100, Washington,
DC 20005. Comments will be publicly
available, including any personally
identifiable or confidential business
information that they contain. Trade
secrets should not be submitted.
Dated: August 30, 2011.
Valerie H. Bonham,
Executive Director, Presidential Commission
for the Study of Bioethical Issues.
[FR Doc. 2011–23030 Filed 9–8–11; 8:45 am]
BILLING CODE 4154–06–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–11–11BJ]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
CDC Diabetes Prevention Recognition
Program (DPRP)—New—Division of
Diabetes Translation, National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) is establishing the
CDC Diabetes Prevention Recognition
Program (DPRP) as authorized by
Section 399–V of Public Law 111–148,
the Patient Protection and Affordable
Care Act. The DPRP will provide a
mechanism for recognizing
organizations that deliver effective,
community-based type 2 diabetes
prevention programs according to
written program standards.
CDC will collect information to
monitor, evaluate, and provide technical
assistance to organizations that apply
for recognition through the DPRP.
Applicant organizations may be publicor private-sector entities. Information
collection will include a one-time, online application form to verify the
organization’s eligibility. Thereafter,
each applicant organization will submit
de-identified program evaluation
(process and outcome) data to CDC
every six months. Information will be
collected electronically. CDC will use
the information to monitor program
fidelity to a CDC-approved diabetes
prevention curriculum, to evaluate its
effectiveness and to provide targeted
technical assistance to applicant
organizations. Contact information for
organizations that fully meet DPRP
standards will be made available on the
DPRP Web site.
OMB approval is requested for three
years. CDC anticipates seeking
continued OMB approval throughout
the lifetime of the DPRP. Participation
in the DPRP is voluntary, and there are
no costs to organizations other than
their time. The total estimated
annualized burden hours are 600.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses
per
respondent
Avg. burden
per
response
(in hrs)
DPRP Application Form ........................
120
1
1
DPRP Evaluation Data .........................
240
2
1
Type of respondent
Form name
Organizations that deliver type 2 diabetes prevention programs.
Dated: August 31, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–22789 Filed 9–8–11; 8:45 am]
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Request for Nominations of
Candidates to Serve on the Breast and
Cervical Cancer Early Detection and
Control Advisory Committee
(BCCEDCAC)
The Centers for Disease Control and
Prevention (CDC) is soliciting
nominations for membership on the
BCCEDCAC. The BCCEDCAC provides
advice and guidance to the Secretary,
the Assistant Secretary for Health, and
the CDC on the early detection and
VerDate Mar<15>2010
16:58 Sep 08, 2011
Jkt 223001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
control of breast and cervical cancer.
The role of the BCCEDCAC is to provide
advice and make recommendations
regarding national program goals and
objectives; implementation strategies;
program priorities, including
surveillance, epidemiologic
investigations, education and training,
information dissemination, professional
interactions and collaborations, and
policy.
Nominations are being sought for
individuals who have expertise and
qualifications necessary to contribute to
the accomplishments of the committee’s
objectives. Nominees will be selected
based on expertise in the field of
medicine, including public health,
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 76, Number 175 (Friday, September 9, 2011)]
[Notices]
[Pages 55914-55915]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-23030]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Request for Comments on Research Across Borders: Proceedings of
the International Research Panel of the Presidential Commission for the
Study of Bioethical Issues
AGENCY: Department of Health and Human Services, Office of the
Assistant Secretary for Health, Presidential Commission for the Study
of Bioethical Issues.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Presidential Commission for the Study of Bioethical Issues
is requesting public comment on the report of the International
Research Panel titled, Research Across Borders: Proceedings of the
International Research Panel of the Presidential Commission for the
Study of Bioethical Issues, available for review at https://www.bioethics.gov.
DATES: To assure consideration, comments must be received by October
11, 2011.
ADDRESSES: Individuals, groups, and organizations interested in
commenting on this study may submit comments by e-mail to
info@bioethics.gov or by mail to the following address: Public
Commentary, Presidential Commission for the Study of Bioethical Issues,
1425 New York Ave., NW., Suite C-100, Washington, DC 20005.
FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications
Director, Presidential Commission for the Study of Bioethical Issues,
1425 New York Avenue, NW., Suite C-100, Washington, DC 20005.
Telephone: 202-233-3960. E-mail: Hillary.Viers@bioethics.gov.
Additional information may be obtained at https://www.bioethics.gov.
SUPPLEMENTARY INFORMATION: On November 24, 2009, the President
established the Presidential Commission for the Study of Bioethical
Issues (Commission) to advise him on bioethical issues generated by
novel and emerging research in biomedicine and related areas of science
and technology. The Commission is charged to identify and promote
policies and practices that assure ethically responsible conduct of
scientific research, healthcare delivery, and technological innovation.
In undertaking these duties, the Commission seeks to identify and
examine specific bioethical, legal, and social issues related to
potential scientific and technological advances; examine diverse
perspectives and possibilities for international collaboration on these
issues; and recommend legal, regulatory, or policy actions as
appropriate.
On October 1, 2010, the U.S. Government disclosed that it had
supported research on sexually transmitted diseases in Guatemala from
1946 to 1948 involving the intentional infection of vulnerable human
populations. In response, President Barack Obama directed the
Presidential Commission for the Study of Bioethical Issues (the
Commission) to ``oversee a thorough fact-finding investigation into the
specifics'' of the U.S. Public Health Service supported research, and
to conduct a review of current human subjects protection ``to determine
if Federal regulations and international standards adequately guard the
health and well-being of participants in scientific studies supported
by the Federal Government.'' The President asked specifically for
assurance ``that current rules for research participants protect people
from harm or unethical treatment, domestically as well as
internationally.'' President Obama directed the Commission to consult
with its counterparts in the global community and to seek the insight
of international experts as part of its work on contemporary
protections for human subjects of research. The Commission
[[Page 55915]]
assembled a subcommittee called the International Research Panel, which
met three times in 2011. The proceedings of the International Research
Panel are now available for public review and comment at the
Commission's Web site, www.bioethics.gov.
Please address comments by e-mail to info@bioethics.gov, or by mail
to the following address: Public Commentary, Presidential Commission
for the Study of Bioethical Issues, 1425 New York Ave., NW., Suite C-
100, Washington, DC 20005. Comments will be publicly available,
including any personally identifiable or confidential business
information that they contain. Trade secrets should not be submitted.
Dated: August 30, 2011.
Valerie H. Bonham,
Executive Director, Presidential Commission for the Study of Bioethical
Issues.
[FR Doc. 2011-23030 Filed 9-8-11; 8:45 am]
BILLING CODE 4154-06-P